EA027831B9 - СПОСОБ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНЫХ СОСТОЯНИЙ С ПРИМЕНЕНИЕМ S-[4-(3-ФТОР-3-МЕТИЛБУТИРИЛОКСИ)БУТ-2-ИНИЛ]6α,9α-ДИФТОР-17α-(ФУРАН-2-ИЛ)КАРБОНИЛОКСИ-11β-ГИДРОКСИ-16α-МЕТИЛ-3-ОКСОАНДРОСТА-1,4-ДИЕН-17β-КАРБОТИОАТА - Google Patents

СПОСОБ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНЫХ СОСТОЯНИЙ С ПРИМЕНЕНИЕМ S-[4-(3-ФТОР-3-МЕТИЛБУТИРИЛОКСИ)БУТ-2-ИНИЛ]6α,9α-ДИФТОР-17α-(ФУРАН-2-ИЛ)КАРБОНИЛОКСИ-11β-ГИДРОКСИ-16α-МЕТИЛ-3-ОКСОАНДРОСТА-1,4-ДИЕН-17β-КАРБОТИОАТА

Info

Publication number
EA027831B9
EA027831B9 EA201592283A EA201592283A EA027831B9 EA 027831 B9 EA027831 B9 EA 027831B9 EA 201592283 A EA201592283 A EA 201592283A EA 201592283 A EA201592283 A EA 201592283A EA 027831 B9 EA027831 B9 EA 027831B9
Authority
EA
Eurasian Patent Office
Prior art keywords
oxoandrosta
methylbutyryloxy
carbothioate
ynyl
carbonyloxy
Prior art date
Application number
EA201592283A
Other languages
English (en)
Other versions
EA201592283A1 (ru
EA027831B1 (ru
Inventor
Житен Ранчходбхаи Патель
Гопалкумар Чиманлал Патель
Гаурав Сандживкумар Шетх
Санджай Нандлал Мандхане
Читтури Тринадха Рао
Раджаманнар Тхеннати
Original Assignee
Сан Фарма Адвансед Ресёрч Компани Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сан Фарма Адвансед Ресёрч Компани Лимитед filed Critical Сан Фарма Адвансед Ресёрч Компани Лимитед
Publication of EA201592283A1 publication Critical patent/EA201592283A1/ru
Publication of EA027831B1 publication Critical patent/EA027831B1/ru
Publication of EA027831B9 publication Critical patent/EA027831B9/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003

Abstract

Изобретение относится к способам лечения воспалительных состояний с применением S-[4-(3-фтор-3-метилбутирилокси)бут-2-инил]6α,9α-дифтор-17α-(фуран-2-ил)карбонилокси-11β-гидрокси-16α-метил-3-оксоандроста-1,4-диен-17β-карботиоата (соединения формулы I), нового противовоспалительного соединения андростанового ряда, и способу его получения
EA201592283A 2013-05-28 2014-05-28 СПОСОБ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНЫХ СОСТОЯНИЙ С ПРИМЕНЕНИЕМ S-[4-(3-ФТОР-3-МЕТИЛБУТИРИЛОКСИ)БУТ-2-ИНИЛ]6α,9α-ДИФТОР-17α-(ФУРАН-2-ИЛ)КАРБОНИЛОКСИ-11β-ГИДРОКСИ-16α-МЕТИЛ-3-ОКСОАНДРОСТА-1,4-ДИЕН-17β-КАРБОТИОАТА EA027831B9 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1881MU2013 2013-05-28
PCT/IN2014/000359 WO2014192027A1 (en) 2013-05-28 2014-05-28 Methods for treatment of inflammatory conditions using s-[4-(3-fluoro-3-methylbutyryloxy) but-2-ynyl] 6alpha, 9alpha-difluoro-17alpha-(furan-2-yl) carbonyloxy-11beta -hydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta -carbothioate.

Publications (3)

Publication Number Publication Date
EA201592283A1 EA201592283A1 (ru) 2016-04-29
EA027831B1 EA027831B1 (ru) 2017-09-29
EA027831B9 true EA027831B9 (ru) 2017-12-29

Family

ID=51300796

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201592283A EA027831B9 (ru) 2013-05-28 2014-05-28 СПОСОБ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНЫХ СОСТОЯНИЙ С ПРИМЕНЕНИЕМ S-[4-(3-ФТОР-3-МЕТИЛБУТИРИЛОКСИ)БУТ-2-ИНИЛ]6α,9α-ДИФТОР-17α-(ФУРАН-2-ИЛ)КАРБОНИЛОКСИ-11β-ГИДРОКСИ-16α-МЕТИЛ-3-ОКСОАНДРОСТА-1,4-ДИЕН-17β-КАРБОТИОАТА

Country Status (18)

Country Link
US (1) US9458187B2 (ru)
EP (1) EP3004133B1 (ru)
JP (1) JP6366696B2 (ru)
KR (1) KR20160030085A (ru)
CN (1) CN105431445A (ru)
AU (1) AU2014272640B2 (ru)
BR (1) BR112015029530A8 (ru)
CA (1) CA2912400A1 (ru)
EA (1) EA027831B9 (ru)
ES (1) ES2664019T3 (ru)
IL (1) IL242658A0 (ru)
MX (1) MX2015016283A (ru)
MY (1) MY179214A (ru)
PH (1) PH12015502652A1 (ru)
SG (1) SG11201509680TA (ru)
UA (1) UA117248C2 (ru)
WO (1) WO2014192027A1 (ru)
ZA (1) ZA201508640B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9458187B2 (en) 2013-05-28 2016-10-04 Sun Pharma Advanced Research Company Limited Methods for treatment of inflammatory conditions using S-[4-(3-fleuro-3-methylbutyryloxy)but-2-ynyl]6α, 9α-difluoro-17α-(furan-2-yl) carbonyloxy-11β-hydroxy-16α-methyl-3-oxoandrosta-1,4-diene-17β-carbothioate
WO2016120894A1 (en) * 2015-01-31 2016-08-04 Sun Pharma Advanced Research Company Limited CRYSTALLINE FORM OF S-(4-(3-FLUORO-3-METHYLBUTYRYLOXY)BUT-2-YNYL)6α,9α-DIFLUORO-17α,-(FURAN-2-YL)CARBONYLOXY-11β-HYDROXY-16α-METHY1-3-OXOANDROSTA-1,4-DIENE-17β-CARBOTHIOATE
CN106279341A (zh) * 2015-05-11 2017-01-04 正大天晴药业集团股份有限公司 一种糠酸氟替卡松的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH24267A (en) 1980-02-15 1990-05-29 Glaxo Group Ltd Androstane carbothioates and pharmaceutical compositions containing the same
US7208613B2 (en) 2002-06-20 2007-04-24 Sun Pharmaceutical Industries Limited Synthesis of s-fluoromethyl 6α,9α-difluoro-11β-hydroxy-16α-methyl-17α-propionyloxy-3-oxoandrosta-1,4-diene-17β-carbothioate
GB0225287D0 (en) 2002-10-30 2002-12-11 Glaxo Group Ltd Novel compounds
AR059216A1 (es) * 2006-01-27 2008-03-19 Sun Pharmaceutical Ind Ltd 11b-hidroxiandrosta-4-eno-3-onas
US9458187B2 (en) 2013-05-28 2016-10-04 Sun Pharma Advanced Research Company Limited Methods for treatment of inflammatory conditions using S-[4-(3-fleuro-3-methylbutyryloxy)but-2-ynyl]6α, 9α-difluoro-17α-(furan-2-yl) carbonyloxy-11β-hydroxy-16α-methyl-3-oxoandrosta-1,4-diene-17β-carbothioate

Also Published As

Publication number Publication date
EP3004133B1 (en) 2018-03-07
MY179214A (en) 2020-11-02
AU2014272640B2 (en) 2018-04-05
EA201592283A1 (ru) 2016-04-29
ZA201508640B (en) 2017-09-27
UA117248C2 (uk) 2018-07-10
KR20160030085A (ko) 2016-03-16
BR112015029530A8 (pt) 2019-12-17
CA2912400A1 (en) 2014-12-04
JP2016520122A (ja) 2016-07-11
US9458187B2 (en) 2016-10-04
BR112015029530A2 (pt) 2017-07-25
ES2664019T3 (es) 2018-04-18
AU2014272640A1 (en) 2015-11-26
MX2015016283A (es) 2016-03-11
EP3004133A1 (en) 2016-04-13
SG11201509680TA (en) 2015-12-30
JP6366696B2 (ja) 2018-08-01
CN105431445A (zh) 2016-03-23
IL242658A0 (en) 2016-02-01
US20160102117A1 (en) 2016-04-14
EA027831B1 (ru) 2017-09-29
PH12015502652A1 (en) 2016-03-07
WO2014192027A1 (en) 2014-12-04

Similar Documents

Publication Publication Date Title
PH12018500981A1 (en) Treatment of osteoarthritis
PH12016501192B1 (en) Tetrahydropyridopyrazines modulators of gpr6
MX2016002794A (es) Compuestos antiproliferativos.
NZ711192A (en) Process for making benzoxazepin compounds
EA201691648A1 (ru) Способ получения противогрибковых соединений
EA201691649A1 (ru) Способ получения противогрибковых соединений
IN2014MU00675A (ru)
EA201690763A1 (ru) Лечение рака поджелудочной железы
GEP20196974B (en) A novel crystalline form of a benzimidazole derivative and a preparation method thereof
MX2015013589A (es) Proceso e intermediario para la preparacion de pregabalina.
EA027831B9 (ru) СПОСОБ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНЫХ СОСТОЯНИЙ С ПРИМЕНЕНИЕМ S-[4-(3-ФТОР-3-МЕТИЛБУТИРИЛОКСИ)БУТ-2-ИНИЛ]6α,9α-ДИФТОР-17α-(ФУРАН-2-ИЛ)КАРБОНИЛОКСИ-11β-ГИДРОКСИ-16α-МЕТИЛ-3-ОКСОАНДРОСТА-1,4-ДИЕН-17β-КАРБОТИОАТА
MY191759A (en) Processes for the preparation of pyrimidinylcyclopentane compounds
UA113988C2 (xx) Спосіб стабілізації бета-напівгідрату штукатурного гіпсу
EA201591449A1 (ru) Способы получения противораковых композиций
EA201692246A1 (ru) Способ получения 2,6-диметилбензохинона
GB2564185A (en) Process for the preparation of derivatives of benzodioxole
MX2015011881A (es) Proceso para la preparacion de 3,7-dimetilnonan-1-ol.
PH12017501360A1 (en) Crystalline form of s-(4-3-fluoro-3-methylbutyryloxy)but-2-ynyl)6a,9a-difluoro-17a,-(fluran-2-yl) carbonyloxy-11b-hydroxy-16a-methy1-3-oxoandrosta-1,4-diene-17b-carbothioate
MX364769B (es) Proceso para producir 2-fenil-1, 3-benzoxazoles.
MX2015015346A (es) Procedimiento para la preparacion de intermediarios de acido boronico.
MX2018009943A (es) Proceso para la fabricacion de derivados de 3-piperazin-1-il-propi lamina.
IN2013CH05982A (ru)
IN2013MU02771A (ru)
MX2016010549A (es) Indol- y bencimidazolcarboxamidas como insecticidas y acaricidas.
IN2013MU01524A (ru)

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU